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Abstract—Methicillin-resistant Staphylococcus aureus (MRSA) with exogenous cassette DNA co-
ntaining the methicillin-resistant gene mecA (SCCmec) poses a problem as a drug-resistant bacte-
rium responsible for hospital- and community-acquired infections. The frequency of MRSA
detection has recently been increasing rapidly in Japan, and SCCmec has also been classiﬁed more
diversely into types I–V. A rapid test is essential for early diagnosis and treatment of MRSA
infections, but detection by conventional methods requires at least two days. The newly developed
multiplex PCR lateral ﬂow method allows speciﬁc ampliﬁcation of femA to detect S. aureus, mecA
to detect SCCmec, and kdpC to detect SCCmec type II; moreover, PCR products can be evaluated
visually in about 3 h. In the present study, we developed a PCR lateral ﬂow method for MRSA
using this method and investigated its clinical usefulness in the detection of MRSA. The results
showed a diagnostic concordance rate of 91.7% for MRSA and methicillin-susceptible S. aureus
between bacteriological examination and PCR lateral ﬂow, and a high level of speciﬁcity in PCR
lateral ﬂow. In addition, a higher detection rate for S. aureus using the same sample was observed
for PCR lateral ﬂow (70.2%) than for bacteriological tests (48.6%). The above results show that
PCR lateral ﬂow for MRSA detection has high sensitivity, speciﬁcity, and speed, and its clinical
application as a method for early diagnosis of MRSA infections appears to be feasible.
KEY WORDS: multiplex PCR; lateral ﬂow; MRSA; rapid genetic testing.
INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA)
was ﬁrst reported in Britain in 1961 as Staphylococcus
aureus with exogenous cassette DNA containing the
methicillin-resistant gene mecA (SCCmec) [1]. MRSA is
currently monitored as one of the major causes of hospital-
acquired infections in Japan. However, the Centers for
Disease Control and Prevention (CDC) also reported
deathsduetocommunity-acquiredMRSAin1999.MRSA
also poses a problem as a drug-resistant bacterium
responsibleforcommunity-acquiredinfectionswherethere
arenoriskfactorssuchasahistoryofhospitalization[2,3].
The frequency with which MRSA is detected has recently
been increasing rapidly in Japan, and SCCmec has also
been classiﬁed more diversely into types I–V[ 4]. These
ﬁndings demonstrate that the potential spread of MRSA
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927among immunocompromised individuals could be a more
serious threat than previously considered.
A rapid test method is therefore essential for early
diagnosis and treatment of MRSA infections. However,
detection of MRSA by standard bacteriological testing
requires at least 2 days. Furthermore, recently inves-
tigated and developed methods such as the cefoxitin
(CFX) susceptibility test, the PBP latex agglutination
test, the PNA-FISH method, and real-time PCR require
expensive special measuring instruments and also show
low sensitivity and speciﬁcity [5–9].
The newly developed PCR lateral ﬂow method uses
speciﬁc primers and capture probes for femA, mecA,a n d
kdpC, respectively. A speciﬁc single-stranded biotiny-
lated PCR product is produced by means of asymmetric
PCR using biotinylated and non-biotinylated primers
mixed at a ﬁxed ratio. The capture probe, which binds
speciﬁcally to the single-stranded biotinylated PCR
product, is immobilized on a membrane and forms a
complex there with the single-stranded biotinylated PCR
product and colloidal gold-labeled streptavidin allowing
PCR products to be evaluated visually.
The method allows rapid diagnosis in approximately
3 h and shows high sensitivity and speciﬁcity because of
the PCR and capture probe. Furthermore, multiplex PCR
allows ampliﬁcation and detection of three genes at the
same time. Furthermore, this method renders detection
devices, such as the electrophoresis apparatus, transillumi-
nators, and ﬂuorescence detectors, unnecessary.
In the present study, we investigated the clinical
usefulness of multiplex PCR lateral ﬂow as a novel,
rapid genetic testing method for direct MRSA detection
from clinical samples.
MATERIALS AND METHODS
Materials
We used clinical specimens submitted by the
Department of Pediatrics at Kitasato University Hospital
over the period of December 2009 to February 2010. A
total of 74 specimens were examined, the breakdown of
which was as follows: 24 specimens in which MRSA
was detected by bacteriological testing (14 sputum
specimens, 3 heparinized blood specimens from PF
(pediatric) and SN (anaerobic) blood culture bottles
(Sysmex/bioMérieux) (blood specimens), 2 nasal swab
specimens, 2 skin swab specimens, 1 stool specimen, 1
pus specimen, 1 leachate specimen), 12 specimens in
which methicillin-susceptible S. aureus (MSSA) was
detected (6 sputum specimens, 2 skin swab specimens, 2
pus specimens, 1 nasal swab specimen, 1 cerebrospinal
ﬂuid specimen), 22 specimens containing S. aureus
(comment Staphylococcus sp.) that did not meet the
criteria of our hospital for harvested bacteria (≥10
6 cfu/
ml in sputum, ≥10
4 cfu/ml in urine) (14 sputum
specimens, 5 throat swab specimens, 2 urine
specimens, 1 oral specimen), and 16 specimens in
which S. aureus was not detected (No S. aureus)( 8
sputum specimens, 1 catheter blood specimen, 1
genitourinary catheter specimen, 2 throat swab
specimens, 1 skin swab specimen, 1 bile specimen, 1
cerebrospinal ﬂuid specimen, 1 stool specimen). After
isolation culture, the clinical specimens were stored
frozen at −20°C until analysis in an MR-CL38-PT
refrigerator (Mitsubishi). The approval of the ethics
committee of Kitasato University Hospital School of
Medicine (B Ethics 09–30) was obtained.
Methods
Isolation and Culture
Isolation medium for routine testing of blood and
anaerobic specimens (including catheters) used a Trypti-
case Soy Agar II with 5% Sheep blood (TSA II)/
chocolate (CHO) agar medium, dollargalluskey-modi-
ﬁed BTB (BTB) agar medium, and CDC agar medium
(Becton Dickinson). TSA II and CHO agar medium and
BTB agar medium were used as isolation media for
upper and lower respiratory tract specimens. BTB agar
medium, MacConkey II agar medium with sorbitol,
DHL agar medium (Becton Dickinson), TCBS agar
medium (Eiken), and modiﬁed Skirrow agar medium EX
(Nissui) were used as isolation media for stool speci-
mens. The culture method used involved streak separa-
tion using a platinum loop after application of the
clinical specimens to the medium. The incubation
conditions for media involved in S. aureus detection
were as follows: aerobic, in an environment of 60%±5%
humidity using an IS92 Incubator (Yamato) for TSA II
and BTB agar medium; 5% CO2, in an environment of
85%±5% humidity and 35°C using a TE-HER CP series
CO2 Incubator (Hirasawa) for CHO agar medium;
colonies were identiﬁed after 24 h of incubation.
Identiﬁcation of Species and Drug Susceptibility
A Pos Combo 3.1J Panel (Siemens) was used for
analysis of the biochemical properties of S. aureus. Drug
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concentration (MIC), was determined using the Micro-
Scan WalkAway-96 SI (SIEMENS), fully automatic
bacteria system, which conforms to the microdilution
method recommended by the Clinical and Laboratory
Standards Institute [10, 11]. S. aureus was treated as
MRSA if it displayed sensitivity to either oxacillin
(MPIPC), CFX, or both antibiotics included in the
Pos Combo 3.1J panel at concentrations: MPIPC/
MIC ≥2 μg/ml and CFX/MIC ≥4 μg/ml.
Multiplex PCR Lateral Flow
MRSA SCCmec types in Japan have been
reported to be mostly type II [12, 13]. The multiplex
PCR lateral ﬂow for MRSA was recently developed to
allow simultaneous detection of three genes: femA to
detect S. aureus, mecA to detect SCCmec, and kdpC
to detect SCCmec type II [14].
Pretreatment of Clinical Specimens. Figure 1 shows a
schematicforPCRlateralﬂowoperations.Stoolspecimens
were treated with a QIAGEN Stool kit (Qiagen) and
sputum samples were dispensed at one part purulent
sputum to one part sputum lytic enzyme solution Sputo-
zyme (Kyokuto) and homogenized. Swab and catheter
specimens (throat swab, nasal swab, skin swab, pus,
leachate, oral) were suspended in 700 μl of sterile saline.
Along with the stock bile and cerebrospinal ﬂuid, they
were then treated with lysostaphin.
Nucleic Acid Extraction. After completion of pretreat-
ment, 6.6 μlo f1 0n g / μl lysostaphin solution (Sigma)
was added to 220 μl of clinical specimens and this was
incubated at 37°C for 10 min [15, 16]. After completion
of lysostaphin processing, nucleic acid was extracted
from the clinical specimens using two nucleic acid
extraction kits, the QIAamp DNA Mini Kit (Qiagen) and
CellEaseII (Biocosm), and a comparison was conducted.
Nucleic Acid Extraction with the QIAamp DNA Mini
Kit. After completion of processing with 200 μlo f
lysostaphin-treated sample, 50 μl of nucleic acid extract
was produced from the clinical specimens using the
QIAamp DNA Mini Kit (QIAGEN). The working time
per specimen was approximately 40 min.
Nucleic Acid Extraction with the CellEaseII. Two
microliters of CellEase A, 2 μl of CellEase B, and 5 μl
of clinical sample pretreated with lysostaphin were
added to a 2-ml tube; the mixture was heated at 68°C
for 4 min and then at 94°C for 3 min using a thermal
cycler and used as the nucleic acid extract. The working
time per specimen was approximately 8 min.
Polymerase Chain Reaction. For polymerase chain
reaction (PCR), 5 μl of nucleic acid extract and 25 μlo f
2× Multiplex PCR Master Mix (Qiagen) reagent were
added to a 200-μl tube, three primer sets adjusted to the
concentrations shown below and distilled water were
added and reacted with a total volume of 50 μl.
The primer set for detection of S. aureus used two
forward primers (F), SauFemA-F (5′-ttacctatctctgct
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Fig. 1. PCR lateral ﬂow operation schematic. (Asterisk) PCR was performed after three ethanol precipitation treatments on the heparin blood sample
after nucleic acid extraction.
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gtttcttcttt-Biotin-3′), at a concentration ratio of 0.15 and
0.25 μM, respectively, and the reverse primer (R),
SauFemA-R-bio (5′-Biotin-cactgcataacttccggcaaa-3′),
was adjusted to a concentration of 0.70 μM.
T h ep r i m e rs e tf o rd e t e c t i o no fS C C m e cw a s
similarly adjusted to concentrations of 0.15-μM MecA-
F, 0.25-μM MecA-F-3bio (5′-ttagattgggatcatagcgtcattat-
Biotin-3′), and 0.80-μM MecA-R-bio (5′-Biotin-aattcca
cattgtttcggtctaaaa-3′).
The primer set for detection of SCCmec type II was
adjusted to concentrations of 0.15-μM KdpC-F (5′-
cgcattgtcaaccgtaatatctg-3′), 0.25-μM KdpC-F-3bio (5′-
cgcattgtcaaccgtaatatctg-Biotin-3′), and 0.50-μM KdpC-
R-bio (5′-Biotin-caaactacggcaattcaaatcct-3′). These three
primer sets were mixed in equal amounts and added to
the tube as described above.
Thermal cycling conditions comprised 15 min at
95°C, followed by 50 cycles of 30 s at 94°C, 30 s at 60°C,
15 s at 72°C, followed by 2 min at 72°C. The PCR
equipment used was a GeneAmp® PCR Systems 9700
(Applied Biosystems).
Detection. PCR products detected are shown in
Fig. 2. Detection used lateral ﬂow with a dipstick,
which had a biotin-labeled control probe, the S. aureus
detection probes SauFemA-1P (5′-ctggtggtacatcaaatgc
attccgtca-3′) and SauFemA-2P (5′-ctggtggtacatca
aatgctttccgtca-3′), the SCCmec detection probe MecA-
P( 5 ′-ccaggaatgcagaaagaccaaagcataca-3′), and the
SCCmec type II detection probe KdpC-P (5′-tctaaacca-
gagccagaagcggtcacc-3′) immobilized on the membrane.
These probes immobilized on the membrane were
performed as follows: these probes were spread on the
membrane with brush, followed by membrane heat-
treated at 80°C.
Fourteen microliters of hybridization buffer and
20 μl of PCR product were added to each well of a 96-
well plate and dipsticks left to soak for 15 min. Next, the
dipstick was transferred to a second well to which
streptavidin-gold conjugate (Funakoshi) had been added
and left to stand for 5 min. Fifty microliters of wash
buffer was then added and the dipstick was transferred to
a third well. The dipstick was left to stand for 3 min and
evaluation made from the red line obtained on the
dipstick.
Evaluation. The evaluations of MRSA and other
bacteria are shown in Table 1. Evaluation was made on
the basis of the four red lines on the dipstick: the control
line as a check, the femA line for S. aureus detection, the
mecA line for SCCmec detection, and the kdpC line for
SCCmec type II detection.
Items for which only the control line was
detected were classiﬁed as negative, those for which
the control line and femA line were detected were
classiﬁed as S. aureus, those for which the control
line, femA line, and mecA line were detected were
classiﬁed as MRSA, and those for which the control
line, femA line, mecA line, and kdpC line were
Control line
femA line
mecA line
kdpC line
PCR products
hypridization buffer
Streptavidin-gold conjugate
15 min 5 min
Wash 
buffer 
3 min
Fig. 2. Lateral ﬂow detection schematic.
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In addition, items for which the control line and
mecA line or control line, mecA line, and kdpC line
were detected were classiﬁed as non-S. aureus with
SCCmec and were classiﬁed as other [17].
RESULTS AND DISCUSSION
Results
The results of PCR lateral ﬂow and bacterio-
logical testing are shown in Table 2.T h er e s u l t so f
analysis of the 74 clinical specimens from bacterio-
logical testing and PCR lateral ﬂow showed that
among the 24 specimens identiﬁed as MRSA in
bacteriological testing, 20 were identiﬁed as SCCmec
type II MRSA, and two other types of MRSA by
PCR lateral ﬂow for a total of 22 specimens (91.7%),
with two specimens negative for MRSA (8.3%). A
blood specimen was deemed negative. Among the 12
specimens identiﬁed as MSSA from bacteriological
testing (16.2%), PCR lateral ﬂow showed one speci-
men to be SCCmec type II MRSA (8.3%) and 11
specimens to be MSSA (91.7%). In addition, among
the 22 specimens identiﬁed as Staphylococcus sp.
from bacteriological testing, PCR lateral ﬂow identi-
ﬁed six specimens as MRSA (27.3%) and showed
ten specimens as MSSA (45.5%). Of the MRSA
specimens, ﬁve were of SCCmec type II MRSA and
one of other type MRSA. Among the 16 specimens
identiﬁed as non-S. aureus from bacteriological test-
ing, PCR lateral ﬂow showed one specimen to be
SCCmec type II MRSA (6.3%) and one specimen to
be MSSA (6.3%). The results of the comparison of
nucleic acids extracted using two nucleic acid
extraction kits, the QIAamp DNA Mini Kit (Qiagen)
and CellEaseII (Biocosm), showed differences
between two of the clinical specimens identiﬁed as
non-S. aureus from bacteriological testing. The two
specimens with differences were extracted using the
QIAamp DNA Mini Kit and classiﬁed as other
(Table 2; others/non-S. aureus); extracts that used
the CellEaseII showed negative results.
DISCUSSION
In terms of speed, PCR is a far more useful test
method than bacteriological testing for MRSA infec-
tions, which require early diagnosis and treatment [18].
However, running multiple PCRs in a single tube
presents many difﬁculties from the point of view of
sensitivity, speciﬁcity, and complexity. In the present
study, we developed a novel multiplex PCR lateral ﬂow
method and investigated the clinical usefulness of the
method in MRSA diagnosis. This method uses multiplex
Table 1. Evaluations of MRSA and Other Bacteria
Control line
femA Line 
mecA Line
kdpC Line 
Control line
femA line
mecA line
kdpC line
MRSA type II    MRSA         MSSA      Negative     (          Other * 1                 )
+
+
+
+
+
+
+
-
+
+
-
-
+
-
-
-
+
-
+
+
+
-
+
-
*1 Other: non-S.aureus bacteria with SSCmec
S. intermedius, S. schleiferi, S. ﬂeurettii, S. sciuri, S. epidermidis, S. capitis, S. hominis, S. vitulinus, S. pseudintermedius, S. saprophyticus, S.
equorum, S. haemolyticus, S. saprophyticus, S. kloosii
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specimen in a single tube. Furthermore, using the
dipstick-type lateral ﬂow method, the three genes can
be detected simultaneously with a single stick. In order
to create a single-stranded PCR product, F-3bio was
added and single-stranded DNA was generated using
complementarily associated F-3bio. In addition, sensi-
tivity was improved in the presence of both R-bio and F-
3bio. Single-stranded DNA was detected complementar-
ily with a detection probe, thereby increasing speciﬁcity.
As mentioned above, improvement in both sensitivity
and speciﬁcity is a major feature of this method.
In general, PCR is subject to several problems that
become major causes of contamination including the
time for analysis, the operational processes, and the
operational method for nucleic acid extraction [19]. In
order to develop a more convenient extraction method
with less contamination, we investigated the extraction
of DNA from identical specimens and the detection of S.
aureus with two widely used nucleic acid extraction kits,
the QIAamp DNA Mini Kit (QIAGEN) and CellEaseII
(Biocosm) [20]. The results showed no difference
between detection results for the two kits for 72 of the
74 specimens. The remaining two specimens were
identiﬁed as non-S. aureus by bacteriological testing
and identiﬁed as “other” and “negative” by PCR using
the different DNA extraction kits (Table 2). However, no
difference was observed between the kits in discrim-
ination of MRSA and MSSA. Furthermore, nucleic acid
extraction time with CellEaseII was approximately
8 min in comparison to 40 min with QIAamp DNA
Mini Kit, allowing the time to be reduced by approx-
imately 32 min. This method was considered to allow
extracts to be processed in an airtight state until addition
to PCR, to have little risk of contamination, and to be a
method well-suited to PCR lateral ﬂow.
Three blood specimens identiﬁed as MRSA from
bacteriological tests all initially showed as negative with
PCR lateral ﬂow. The PF (pediatric) blood culture bottle
used for the blood specimens contained activated carbon
particles, an antibiotic adsorbent agent. Since this inhibits
the PCR, centrifugation was required [9]. In addition, three
blood specimens came from the same patient and were
takenduringadministrationof13,200units/6daysofNovo
Heparin (Mochida Pharmaceuticals) to treat disseminated
intravascular coagulation. Blood specimens containing
heparin are generally unsuitable for PCR [21] and the
present results from these blood samples are believed to
have been affected by heparin inhibition of PCR. We
therefore carried out three ethanol precipitation treatments
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932 Nihonyanagi, Kanoh, Okada, Uozumi, Kazuyama, Yamaguchi et al.after nucleic acid extraction from these specimens and ran
a PCR lateral ﬂow. The results showed that MRSA was
detectedintwoofthethreespecimens.Therefore,anucleic
acid extraction method to remove the inﬂuence of
substances such as heparin that inhibit PCR and blood
sampling using an EDTA salt as an anticoagulant may be
necessary for detection from blood specimens.
In the present study, bacteriological testing identi-
ﬁed S. aureus in 36 of the 74 specimens examined
(48.6%), whereas PCR lateral ﬂow identiﬁed S. aureus
in 52 of the specimens (70.2%). Of 12 specimens
identiﬁed as MSSA by bacteriological testing (16.2%),
one was shown to be MRSA by PCR lateral ﬂow
(8.3%). Regarding the clinical specimens that did not
meet the criteria of our hospital for harvested bacteria in
bacteriological tests (≥10
6 cfu/ml in sputum, ≥10
4 cfu/ml
in urine) and were identiﬁed as Staphylococcus sp. from
report comments, six specimens were identiﬁed as MRSA
(27.3%), and ten as MSSA (45.5%) by PCR lateral ﬂow.
Furthermore, among the clinical specimens identiﬁed as
non-S. aureusfrom bacteriological testing, PCR lateral ﬂow
showed one specimen to be MRSA (6.3%) and one
specimen to be MSSA (6.3%). Discrepancies in test
results between the methods were believed to be
attributable to differences in sensitivity. The MRSA and
MSSA diagnostic concordance rate for PCR lateral ﬂow
and bacteriological testing was 91.7% overall and 95.2%
when the PCR-inhibiting blood specimens are excluded. A
discrepancy between bacteriological testing and PCR
lateral ﬂow which was observed for one nasal swab
specimen and was believed to be due to a problem with
the specimen’s treatment and storage. On the basis of our
ﬁndings, PCR lateral ﬂo ww a sc o n s i d e r e dt oh a v eh i g h e r
detection sensitivity than bacteriological testing. In the
currentsituationofincreasingMRSAinfections,thereisthe
risk that a carrier bearing quantities of bacteria difﬁcult to
detect by bacteriological testing may become an infection
source for hospital-acquired infections. This will need
attention in the control of hospital-acquired infection in
thefuture,andwebelievethismethodwillbeveryusefulas
one of these controls.
Bacteria other than MRSA have also been reported
to have the mecA and kdpC genes [22]. However,
detection of the femA and mecA genes and mecA and
kdpC genes was a prerequisite for identiﬁcation of
MRSA in the present study. It was believed, therefore,
that bacteria other than MRSA had virtually no effect on
test results from PCR lateral ﬂow. In future, however,
bacteriological testing and comparative studies should
be carried out with more test materials and the effect of
non-speciﬁc reactions due to bacteria other than MRSA
should be investigated.
In conclusion, multiplex PCR lateral ﬂow appears
to be useful as a test method for MRSA detection with
high sensitivity, speciﬁcity, and speed. It is feasible for
clinical application in MRSA infections, which require
early diagnosis and treatment.
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